ATE255563T1 - Therapeutisch nützliche chinoline und quinazoline - Google Patents

Therapeutisch nützliche chinoline und quinazoline

Info

Publication number
ATE255563T1
ATE255563T1 AT98303897T AT98303897T ATE255563T1 AT E255563 T1 ATE255563 T1 AT E255563T1 AT 98303897 T AT98303897 T AT 98303897T AT 98303897 T AT98303897 T AT 98303897T AT E255563 T1 ATE255563 T1 AT E255563T1
Authority
AT
Austria
Prior art keywords
chem
formula
optionally substituted
ring
quinazolines
Prior art date
Application number
AT98303897T
Other languages
English (en)
Inventor
David Nathan Abraham Fox
Simon John Mantell
Alan John Collis
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE255563T1 publication Critical patent/ATE255563T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Mushroom Cultivation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98303897T 1997-06-05 1998-05-18 Therapeutisch nützliche chinoline und quinazoline ATE255563T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9711650.3A GB9711650D0 (en) 1997-06-05 1997-06-05 Compounds useful in therapy

Publications (1)

Publication Number Publication Date
ATE255563T1 true ATE255563T1 (de) 2003-12-15

Family

ID=10813629

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98303897T ATE255563T1 (de) 1997-06-05 1998-05-18 Therapeutisch nützliche chinoline und quinazoline

Country Status (11)

Country Link
US (2) US6048864A (de)
EP (1) EP0887344B1 (de)
JP (1) JP3163281B2 (de)
AT (1) ATE255563T1 (de)
BR (1) BR9801778A (de)
CA (1) CA2239603C (de)
DE (1) DE69820159T2 (de)
DK (1) DK0887344T3 (de)
ES (1) ES2210673T3 (de)
GB (1) GB9711650D0 (de)
PT (1) PT887344E (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
GB9711650D0 (en) * 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
US6238275B1 (en) 1998-08-19 2001-05-29 Alva Wesley Metcalf Contained direct particle beam flow abrasion system
US6191300B1 (en) 1999-04-16 2001-02-20 Eastman Chemical Company Process for the preparation of cyclopropylacetonitrile
KR100420663B1 (ko) * 2001-01-09 2004-03-02 주식회사 켐온 퀴놀린 유도체, 그의 제조방법 및 그를 포함하는 약학적조성물
US7071216B2 (en) * 2002-03-29 2006-07-04 Chiron Corporation Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
US8299108B2 (en) * 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
ES2423800T3 (es) * 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
DE602004021838D1 (de) 2003-10-16 2009-08-13 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
UA117296C2 (uk) 2008-07-31 2018-07-10 Сіномікс, Інк. Способи і проміжні сполуки для одержання підсилювачів солодкого смаку
PT2334639E (pt) * 2008-09-10 2013-04-26 Celgene Corp Processos para a preparação de compostos de aminossulfona
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
US9458131B2 (en) * 2011-11-08 2016-10-04 Emory University Compounds and compositions used to epigenetically transform cells and methods related thereto
EP3593648B1 (de) 2012-08-06 2021-07-14 Firmenich Incorporated Änderungsmittel für süssen geschmack
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
WO2018051306A1 (en) 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
KR20240032157A (ko) 2017-05-02 2024-03-08 노파르티스 아게 병용 요법
US11945813B2 (en) 2018-08-07 2024-04-02 Firmenich Incorporated 5-substituted 4-amino-1H-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof
MX2021013817A (es) 2019-05-13 2021-12-14 Novartis Ag Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3956495A (en) * 1973-10-30 1976-05-11 Eli Lilly And Company 2,4-Diaminoquinazolines as antithrombotic agents
US4656174A (en) * 1982-07-24 1987-04-07 Pfizer Inc. Quinoline therapeutic agents
GB8506174D0 (en) * 1985-03-09 1985-04-11 Pfizer Ltd 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
GB8719378D0 (en) * 1987-08-15 1987-09-23 Pfizer Ltd Antiarrythmic agents
IL88507A (en) * 1987-12-03 1993-02-21 Smithkline Beckman Intercredit 2,4-diaminoquinazolines, process for their preparation and pharmaceutical compositions comprising them
US6015819A (en) * 1992-11-13 2000-01-18 Synaptic Pharmaceutical Corporation Use of alpha-1C specific compounds to treat benign prostatic hyperplasia
IT1270993B (it) * 1994-03-18 1997-05-26 Recordati Chem Pharm Derivati chinzolilamminici attivi come alfa-antagonisti
GB9526546D0 (en) * 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
IL120302A0 (en) * 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
GB9711650D0 (en) * 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy

Also Published As

Publication number Publication date
CA2239603C (en) 2003-07-22
CA2239603A1 (en) 1998-12-05
MX9804482A (es) 1998-12-31
DE69820159D1 (de) 2004-01-15
US6417194B1 (en) 2002-07-09
DK0887344T3 (da) 2004-03-08
PT887344E (pt) 2004-02-27
ES2210673T3 (es) 2004-07-01
EP0887344A1 (de) 1998-12-30
BR9801778A (de) 2000-03-21
JP3163281B2 (ja) 2001-05-08
GB9711650D0 (en) 1997-07-30
JPH1112274A (ja) 1999-01-19
US6048864A (en) 2000-04-11
DE69820159T2 (de) 2004-05-27
EP0887344B1 (de) 2003-12-03

Similar Documents

Publication Publication Date Title
ATE255563T1 (de) Therapeutisch nützliche chinoline und quinazoline
YU31699A (sh) Hinolin i hinazolin jedinjenja korisna u terapiji,naročito u tretmanu benigne hiperplazije prostate
CA2236814A1 (en) Quinoline and quinazoline compounds useful in therapy
FI904327A0 (fi) N-substituerad-4-pyrimidinaminer och -pyrimidindiaminer, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
NZ234249A (en) Optionally heterocyclically-substituted pyridine derivatives and pharmaceutical compositions
DE69811556D1 (de) Chinoline und Chinazoline Verbindungen und ihre therapeutische Anwendung
ATE209199T1 (de) Chinolin und chinazolin derivate zur behandlung von arthritis
ATE155465T1 (de) Phenoxy- oder phenoxyalkyl-piperidine als antivirale mittel
FI914007A0 (fi) 4-substituerade dihydropyrido (4,3-d) pyrimidiner som smaertslindrande och lokala inflammationshaemmande medel vid vaord av hudsjukdomar.
ATE140229T1 (de) Benzoxazepinon-verfahren
DE69428206D1 (de) Chinolincarbonsäurederivate und ihre salze
DE69110219D1 (de) 3-(1H-Indazol-3-yl)-4-pyridiname, Verfahren und Zwischenprodukte zu ihrer Herstellung und ihre Verwendung als Arzneimittel.
ATE112569T1 (de) Verwendung von imidazopyrazolderivaten als analgesische und antiinflammatorische mittel.
DE3781783D1 (de) N-alkyl-derivate von 2-amino-6,7-dimethoxytetralin, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen mit antihypertensiver wirkung.
CO4650138A1 (es) Compuestos de quinolina y de quinazolina utiles en terapia

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0887344

Country of ref document: EP

REN Ceased due to non-payment of the annual fee